Viking Therapeutics’ experimental weight loss tablet VK2735 showed potential in reducing weight by up to 3.3% in a small early-stage trial, meeting market expectations and boosting the company’s shares by 15%. The drug, given orally, is seen as a more convenient alternative to under-the-skin injections from competitors like Eli Lilly and Novo Nordisk. Viking plans to continue testing higher doses of the drug in healthy or overweight volunteers and initiate a mid-stage study in obese patients. The company believes that patients who see success with the oral version may be more willing to transition to injectable options for further weight loss.
Source link
Viking Therapeutics’ Weight-loss Tablet Shows Promise in Small Study
